The medication showed promise in improving patients' capacity for self-care activities like dressing and eating.
Lecanemab (Leqembi) was unanimously recommended by the Food and Drug Administration (FDA) panel to slow the course of Alzheimer’s. It represents a significant advance in Alzheimer’s care. Lecanemab’s clinical trial outcomes were described as “robust,” “clear,” and “consistent” by experts.
For the 6.5 million people suffering by Alzheimer’s disease, it gives hope. There is currently no treatment for Alzheimer’s. In its latter phases, serious brain function loss, starvation, dehydration, and infections that might be fatal can all result.
The Centres for Medicare and Medicaid Services (CMS), however, have put a stipulation to the coverage of Lecanemab. For patients who sign up for a nationwide registry, CMS will pay for the medication. The registration procedure and deadline worry patients, physicians, and carers.
Details about lecanemab
Lecanemab proved in clinical trials to slow cognitive deterioration in those with Alzheimer‘s disease or mild cognitive impairment by 27%. The medication also showed promise for improving patients’ capacity for self-care activities including dressing and eating.
Lecanemab side effects include reactions at the injection site and amyloid-related imagining abnormalities (ARIA), which are marked by brain enlargement. The current label for lecanemab states that medical professionals must follow patients using MRI images to look for indications of ARIA.
The drug lecanemab does not treat Alzheimer’s disease. However for patients with the disease in its early stages, a medication that has received FDA approval alters the path of the illness. Lecanemab’s producers reportedly set the price at $26,500 per year.
For those with early-stage Alzheimer’s who have been diagnosed with increased beta-amyloid, lecanemab is appropriate. The medicine was evaluated on individuals with early Alzheimer’s dementia and MCI brought on by Alzheimer’s, according to the Alzheimer’s Association. In the brains of these people, beta-amyloid plaques have accumulated. Clinical studies were not open to persons with more advanced stages of Alzheimer’s disease or those without overt symptoms. Therefore, there is no proof that lecanemab would be effective in treating Alzheimer’s patients with more complex cases.